4D Molecular Therapeutics gets FDA RMAT status for macular edema treatment
Source: SeekingAlpha
2025-05-01 10:11:30 ET
More on 4D Molecular Therapeutics
- 4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression
- Cantor analysts call for RFK Jr. replacement following ousting of Marks at FDA
- How Peter Marks' FDA departure is impacting pharma, biotech stocks
- Seeking Alpha’s Quant Rating on 4D Molecular Therapeutics
- Historical earnings data for 4D Molecular Therapeutics
Read the full article on Seeking Alpha
For further details see:
4D Molecular Therapeutics gets FDA RMAT status for macular edema treatment
4D Molecular Therapeutics Inc.
NASDAQ: FDMT
FDMT Trading
-0.94% G/L:
$8.37 Last:
191,522 Volume:
$8.55 Open:
FDMT Latest News
FDMT Stock Data
$519,643,507
47,993,463
N/A
51
N/A
Biotechnology & Life Sciences
Healthcare
US
Emeryville
